Study Finds Energy Drinks May Cause Cardiovascular Risks
June 4th 2019Health care professionals can play an important role in counseling patients about the dangers of energy drinks. Individuals taking medications associated with QT prolongation such as certain antiarrhythmics, antibiotics, antidepressants, and antipsychotics, should avoid consuming energy drinks.
Feedback Sought on Special Packaging Proposal for Certain Opioid Medications
May 31st 2019The agency has opened a public docket to solicit feedback on the proposed requirement, which would necessitate certain immediate-release opioid analgesics be made available in fixed-quantity, unite-of-use blister packaging.
Drug's Expanded Use for Treatment of Bipolar Depression Granted FDA Approval
May 28th 2019Cariprazine also is approved to treat manic or mixed episodes associated with bipolar depression in adults. The new indication makes this drug the first and only dopamine and serotonin partial agonist to treat the full spectrum of bipolar I symptoms in manic, mixed, and depressive episodes.
Nasal Spray Approved By FDA for Treating Certain Seizures in Patients with Epilepsy
May 20th 2019Left untreated, seizure clusters can increase the risk of physical injury, neurological damage, prolonged seizures, and status epilepticus, according to UCB, and many diagnosed patients with may go untreated when preferred treatment options are unavailable.
Aflibercept for Diabetic Retinopathy Receives FDA Approval
May 14th 2019The PANORAMA trial showed that by 1 year, 20% of untreated patients developed proliferative diabetic eye disease, and aflibercept injection reduced this risk by 85% to 88% when administered using an every 16-week or eight-week dosing regimen, respectively.
Increase of Pediatric Nurse Practitioners Needed to Overcome Shortage
May 7th 2019With approximately 18,100 PNPS and 50,000 primary care pediatricians currently in the workforce, there are insufficient numbers of pediatric primary care providers to care for the increasingly demanding and complex needs of children.
First Vaccine for Prevention of Dengue Disease in Endemic Regions Granted FDA Approval
May 2nd 2019The drug application was granted the FDA’s Priority Review designation, as well as a Tropical Disease Priority Review Voucher under a program intended to encourage development of new drugs and biologics for the prevention and treatment of certain tropical diseases.